• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国际泌尿病理学会(SIU-ICUD)关于膀胱癌的病理学。

SIU-ICUD on bladder cancer: pathology.

机构信息

Department of Pathology, Hopital Tenon, HUEP, Sorbonne University, Paris, France.

Department of Urology, Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.

出版信息

World J Urol. 2019 Jan;37(1):41-50. doi: 10.1007/s00345-018-2466-5. Epub 2018 Sep 14.

DOI:10.1007/s00345-018-2466-5
PMID:30218308
Abstract

Many changes have been made during these last years and concepts for understanding bladder cancer have evolved. We make an update with the latest findings of the WHO (World Health Organistaion) 2016, ICCR (International Collaboration on Cancer Reporting) and other official organisms and try to show the latest developments. In this document we provide new consensus guidelines and insights. We kept this document short and concise providing consensus guidelines to clinicians for the best patient care, it should be easy to understand for a non pathologists. We focussed on several burning issues, such as the anatomical and histological understanding of the bladder wall, the prognostic significance of grading and the most challenging problems in staging, we underline our needs from the clinicians such as clinical information, we further discuss the histological subtypes of bladder cancer, which is an extremely important issue in the light of molecular classifications and give prognostic insights. Furthermore, we discuss the ICCR worldwide consensus reporting, urinary cytology with the Paris system and several issues such as frozen section specimen.

摘要

在过去的几年中,已经发生了许多变化,对膀胱癌的理解也有所发展。我们根据世界卫生组织(WHO)2016 年、国际癌症报告合作组织(ICCR)和其他官方机构的最新发现进行了更新,并尝试展示最新的发展。在本文档中,我们提供了新的共识指南和见解。我们保持文档简短明了,为临床医生提供最佳患者护理的共识指南,以便非病理学家也能轻松理解。我们关注了几个热点问题,如膀胱壁的解剖和组织学理解、分级的预后意义以及分期中最具挑战性的问题,强调了我们对临床医生的需求,如临床信息,我们进一步讨论了膀胱癌的组织学亚型,鉴于分子分类,这是一个极其重要的问题,并提供了预后见解。此外,我们还讨论了 ICCR 全球共识报告、巴黎系统的尿细胞学以及冷冻切片标本等几个问题。

相似文献

1
SIU-ICUD on bladder cancer: pathology.国际泌尿病理学会(SIU-ICUD)关于膀胱癌的病理学。
World J Urol. 2019 Jan;37(1):41-50. doi: 10.1007/s00345-018-2466-5. Epub 2018 Sep 14.
2
A practical guide to bladder cancer pathology.膀胱癌病理学实用指南。
Nat Rev Urol. 2018 Mar;15(3):143-154. doi: 10.1038/nrurol.2018.2. Epub 2018 Jan 31.
3
Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.流行病学、预防、筛查、诊断和评估:国际尿控协会-国际泌尿外科学会联合咨询关于膀胱癌的更新。
World J Urol. 2019 Jan;37(1):3-13. doi: 10.1007/s00345-018-2436-y. Epub 2018 Aug 13.
4
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.1973 年和 2004/2016 年世界卫生组织分级分类系统在非肌肉浸润性膀胱癌中的预后性能和可重复性:欧洲泌尿外科学会非肌肉浸润性膀胱癌指南小组系统评价。
Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28.
5
The pathology of bladder cancer: An update on selected issues.膀胱癌的病理学:特定问题的最新进展。
BJU Int. 2006 Dec;98(6):1161-5. doi: 10.1111/j.1464-410X.2006.06445.x. Epub 2006 Jul 28.
6
Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR).用于肿瘤肾活检报告的数据集:国际癌症报告协作组织(ICCR)的建议。
J Clin Pathol. 2019 Sep;72(9):573-578. doi: 10.1136/jclinpath-2019-205959. Epub 2019 Jul 12.
7
SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.国际泌尿外科学会-国际尿路上皮癌联盟咨询意见:膀胱癌治疗——肌层浸润性膀胱癌处理。
World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25.
8
Contemporary Grading and Staging of Urothelial Neoplasms of the Urinary Bladder: New Concepts and Approaches to Challenging Scenarios.膀胱尿路上皮肿瘤的当代分级与分期:应对复杂情况的新概念与方法
Surg Pathol Clin. 2018 Dec;11(4):775-795. doi: 10.1016/j.path.2018.07.006.
9
Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) urological tumour registry.英国膀胱癌的分期、分级和病理特征:英国泌尿外科医师协会(BAUS)泌尿外科肿瘤登记处。
BJU Int. 2014 Jun;113(6):924-30. doi: 10.1111/bju.12468. Epub 2014 Jan 22.
10
Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder.分期及世界卫生组织分类系统在膀胱T1期尿路上皮癌中的预后意义
Curr Opin Urol. 2015 Sep;25(5):427-35. doi: 10.1097/MOU.0000000000000202.

引用本文的文献

1
Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.膀胱癌样本的处理与报告:病理学家的观点
Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021.
2
Tumor cell invasion in blood vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy.免疫组织化学评估的肿瘤细胞血管侵犯与接受根治性膀胱切除术治疗的膀胱癌患者的生存降低有关。
Diagn Pathol. 2021 Nov 22;16(1):109. doi: 10.1186/s13000-021-01171-7.
3
Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group.

本文引用的文献

1
Implementing The Paris System for Reporting Urinary Cytology results in a decrease in the rate of the "atypical" category and an increase in its prediction of subsequent high-grade urothelial carcinoma.在尿细胞学报告中实施巴黎系统可降低“非典型”类别比例,并提高其对随后发生高级别尿路上皮癌的预测能力。
Cancer Cytopathol. 2018 Mar;126(3):207-214. doi: 10.1002/cncy.21958. Epub 2017 Dec 26.
2
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.1973 年和 2004/2016 年世界卫生组织分级分类系统在非肌肉浸润性膀胱癌中的预后性能和可重复性:欧洲泌尿外科学会非肌肉浸润性膀胱癌指南小组系统评价。
Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28.
3
采用多学科方法管理非肌层浸润性膀胱癌患者的最新进展:西班牙泌尿生殖肿瘤学(SOGUG)工作组的实用建议
Cancers (Basel). 2021 Sep 23;13(19):4762. doi: 10.3390/cancers13194762.
4
Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.膀胱癌更新的病理学报告标准:活检、经尿道切除术和根治性膀胱切除术。
World J Urol. 2022 Apr;40(4):915-927. doi: 10.1007/s00345-021-03831-1. Epub 2021 Sep 23.
5
Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).膀胱癌-膀胱切除术、膀胱前列腺切除术和憩室切除术标本报告数据集:国际癌症报告合作组织(ICCR)的建议。
Virchows Arch. 2020 Apr;476(4):521-534. doi: 10.1007/s00428-019-02727-1. Epub 2020 Jan 8.
Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.单纯经尿道切除术是否足以诊断组织学变异型?一项单中心研究。
Urol Oncol. 2017 Aug;35(8):528.e1-528.e5. doi: 10.1016/j.urolonc.2017.03.024. Epub 2017 Apr 19.
4
Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.膀胱癌病理分期面临的挑战:鉴于近期有关膀胱组织解剖学差异的研究和观察结果,对评估病理分期新方法的建议
Adv Anat Pathol. 2017 May;24(3):113-127. doi: 10.1097/PAP.0000000000000152.
5
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.肌层浸润性膀胱癌分子亚型对新辅助化疗后反应和生存预测的影响。
Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.
6
Transurethral en bloc resection of nonmuscle invasive bladder cancer: trend or hype.非肌层浸润性膀胱癌经尿道整块切除术:趋势还是炒作?
Curr Opin Urol. 2017 Mar;27(2):182-190. doi: 10.1097/MOU.0000000000000377.
7
Clonal evolution of chemotherapy-resistant urothelial carcinoma.化疗耐药性尿路上皮癌的克隆进化
Nat Genet. 2016 Dec;48(12):1490-1499. doi: 10.1038/ng.3692. Epub 2016 Oct 17.
8
Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.膀胱乳头状尿路上皮癌的分级异质性分析:CDKN2A缺失在FGFR3通路中早期作用的支持证据
Histopathology. 2017 Jan;70(2):281-289. doi: 10.1111/his.13063. Epub 2016 Oct 28.
9
The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.淋巴血管侵犯在膀胱癌中的预后作用。
Nat Rev Urol. 2016 Aug;13(8):471-9. doi: 10.1038/nrurol.2016.126. Epub 2016 Jul 19.
10
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.2016 年更新版 EAU 肌层浸润性和转移性膀胱癌临床实践指南。
Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. Epub 2016 Jun 30.